COVIMECTIN 6 Tablet is a high-quality oral antiparasitic formulation containing Ivermectin at a strength of 6 mg. Ivermectin is a widely used macrocyclic lactone compound derived from the avermectin family, originally isolated from Streptomyces avermitilis. It is recognized for its broad-spectrum activity against various parasitic organisms, including nematodes, ectoparasites, and certain arthropods, making it a cornerstone therapy in both individual patient care and public health initiatives.
The mechanism of action of Ivermectin in COVIMECTIN 6 involves its selective binding to glutamate-gated chloride channels in nerve and muscle cells of invertebrates. This results in increased permeability of the cell membrane to chloride ions, leading to hyperpolarization, paralysis, and eventual death of the parasite. Due to the absence of such chloride channels in humans and the drug’s limited ability to cross the blood-brain barrier, COVIMECTIN 6 maintains a high safety margin when used appropriately.
COVIMECTIN 6 is indicated for the treatment of various parasitic diseases. These include intestinal strongyloidiasis caused by Strongyloides stercoralis, onchocerciasis caused by Onchocerca volvulus, and ectoparasitic infestations like scabies and lice. It is also used as part of national and global campaigns for the control and elimination of lymphatic filariasis. The 6 mg dosage offers flexibility, especially in weight-based dosing or pediatric and geriatric populations, where precise titration is important for safety and efficacy.
The administration of COVIMECTIN 6 is oral, typically given on an empty stomach with a full glass of water. Depending on the condition, a single dose may be sufficient, though follow-up or repeat dosing might be necessary for certain infections or in regions with high reinfection rates. When used in scabies or lice treatment, it is often combined with hygiene measures and topical therapies to enhance success and prevent recurrence.
Pharmacokinetically, Ivermectin is rapidly absorbed and reaches peak plasma concentrations within four to five hours. It has a relatively long half-life and is primarily excreted through the feces. The formulation of COVIMECTIN 6 ensures stable bioavailability and consistent therapeutic effect. Common side effects are generally mild and include nausea, dizziness, abdominal discomfort, or skin rashes. In cases involving heavy parasitic load, patients may experience immune responses such as fever, joint pain, or lymph node swelling, particularly in infections involving microfilariae.
COVIMECTIN 6 is contraindicated in children under 15 kg body weight, pregnant and lactating women, and in individuals with known hypersensitivity to Ivermectin. Medical caution is advised in patients with neurological disorders or hepatic impairment. Interaction with other central nervous system-active medications should be evaluated by the prescribing physician. Alcohol consumption is not recommended during treatment.
During the COVID-19 pandemic, Ivermectin received attention for off-label use as part of experimental or adjunctive therapy under regulated clinical settings. While such applications remain controversial and are not universally approved, the pharmacological versatility of Ivermectin has sparked further research into its antiviral and immunomodulatory potential. However, COVIMECTIN 6 should only be used for these purposes under expert supervision and in accordance with updated clinical guidelines.
From a manufacturing standpoint, COVIMECTIN 6 is produced in WHO-GMP certified facilities with strict adherence to pharmaceutical quality standards. The tablets are film-coated to ensure palatability and moisture resistance and are packed in secure blister packaging to preserve shelf stability and maintain product integrity. The dosage form is optimized for ease of swallowing, especially important in populations with compliance challenges.
Description provided by bluepill express.
FIEO Registered
Export Ready
